Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
|Articles|October 25, 2013
- Genitourinary Cancers
- Volume 1
- Issue 1
Frontline Treatment of Kidney Cancer With Pazopanib and Sunitinib
Author(s)James J. Hsieh, MD, PhD
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the frontline treatment of patients with kidney cancer with pazopanib and sunitinib.
Advertisement
James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the frontline treatment of patients with kidney cancer with pazopanib and sunitinib.
The development of drugs that target angiogenesis and signal transduction pathways in the treatment of metastatic renal cell carcinoma has led to improved survival rates for patients.
Articles in this issue
almost 13 years ago
Patient-Centered Management of Metastatic Renal Cell Carcinomaalmost 13 years ago
Expert Perspectives: Androgen-Deprivation Therapy in Prostate Canceralmost 13 years ago
Treatment of Advanced Renal Cell Carcinomaalmost 13 years ago
Treatment Pathways and Sequencing Strategies in CRPCalmost 13 years ago
Therapeutic Strategies for Managing Bone Health in Prostate Canceralmost 13 years ago
Immunotherapy in CRPCalmost 13 years ago
Factors in Choosing First-Line Targeted Therapy in RCCalmost 13 years ago
Immune Response in Patients with RCCalmost 13 years ago
Sequencing Agents to Treat Castration-Resistant Prostate CancerAdvertisement
Related to this article
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Durability of PFS and OS Benefit vs. Historical Control
3
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
4
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
5